Workflow guide · Decision support
How a Small Fund Prepares a Biotech Investment Committee Brief
Compress a week of company news and catalyst changes into an evidence trail the investment committee can challenge and act on.
The situation
When this workflow becomes useful
The fund is reviewing a new position, reconsidering an existing holding, or preparing for a major clinical or regulatory event.
Best fit
Portfolio managers, analysts, associates, and operations leads at small healthcare and event-driven investment funds.
The challenge
Why the obvious approach breaks down
Research is often distributed across notes, chat messages, spreadsheets, and memory. The committee needs the latest facts without losing the history of how the thesis evolved.
How to think about the task
The reasoning behind the workflow
An investment committee brief should make a decision easier to challenge. It is not a complete archive of everything known about the company, and it is not a polished retelling of management’s narrative. The brief should identify the decision, expose the assumptions behind it, and show what changed since the last review.
Biotech makes this discipline especially important because the evidence is sequential. Early signals, longer follow-up, regulatory feedback, financing, and competitor events accumulate over time. A committee that sees only the latest presentation may miss how frequently the timeline or development story has changed.
Begin with the decision and evidence threshold
The first page should state whether the committee is considering initiation, adding, reducing, exiting, or maintaining exposure. It should also state what evidence would justify a different decision. Without that threshold, the meeting can become a broad company discussion that ends without an explicit conclusion.
Separate four layers of information
Reported facts, management interpretation, market expectations, and the team’s inference should not be blended together. A trial result is a fact; management’s description of differentiation is interpretation; consensus expectations belong to the market layer; the fund’s probability adjustment is its own inference. Showing the layers makes disagreements easier to locate.
Make uncertainty visible rather than comprehensive
The strongest brief is often shorter because it concentrates on unresolved questions. A risk table should show the assumption, supporting evidence, contradictory evidence, next resolution point, and portfolio consequence. That structure is more useful than adding background pages that do not change the decision.
Illustrative example
Illustrative pre-readout committee review
Before a Phase 3 readout, the committee may need to decide whether current exposure is consistent with the fund’s loss tolerance. The brief can show the Phase 2 evidence, differences in the pivotal design, competitor precedent, expected event window, cash position, and scenarios for efficacy, safety, and timing.
The meeting should end with more than a view on the drug. It should record the approved exposure, the evidence that would trigger reconsideration before the event, and the person responsible for monitoring each trigger. That record becomes the baseline for the post-readout review.
Questions to answer before making a decision
- What exact decision must the committee make?
- What changed since the prior review?
- Which assumptions carry most of the valuation or downside?
- What new evidence would force the team to revisit the decision?
The workflow
A repeatable way to do the work
- 01
State the decision the committee must make and the evidence threshold for changing exposure.
- 02
Build a chronological timeline of material company and competitor updates.
- 03
Separate reported facts, management interpretation, market expectations, and the team’s inference.
- 04
Show upcoming catalysts, date confidence, downside scenarios, and correlated portfolio exposure.
- 05
End with unresolved questions, assigned owners, and a deadline for the next review.
Monitoring checklist
Signals to keep visible
Common mistakes
- Retelling the company story without defining a decision
- Mixing management claims with independently verified facts
- Hiding uncertainty behind a long document
Output and outcome
What good looks like
Deliverable
A decision-oriented memo with a current thesis, evidence timeline, catalyst map, risk table, and named follow-ups.
Practical outcome
The committee can focus on the assumptions that matter, compare the current thesis with prior evidence, and leave the meeting with explicit decisions and ownership.
Where BioPharmSignal fits
Reduce the collection work around the decision.
Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep the relevant tickers and keywords visible. The workflow still requires independent research and judgment.
Frequently asked questions
Who is this workflow for?
It is designed for small biotech fund teams and adjacent biotech research users who need a repeatable, source-linked way to complete this task.
What should this workflow produce?
A decision-oriented memo with a current thesis, evidence timeline, catalyst map, risk table, and named follow-ups.
What is the practical benefit?
The committee can focus on the assumptions that matter, compare the current thesis with prior evidence, and leave the meeting with explicit decisions and ownership.
Related workflows